An official with the Food and Drug Administration (FDA) says the agency is “actively” exploring a regulatory framework for cannabidiol (CBD), with plans to prioritize the move in the coming months.
At a webinar hosted by Alliance for a Strong FDA, Kimberlee Trzeciak, who serves as the FDA’s Deputy Commissioner for Policy, Legislation, and International Affairs, says that either this year or next the agency is planning to establish “an appropriate regulatory framework for CBD.”
“In almost every neighborhood you go to, you can see stores on the corners that are marketing CBD and kratom and others,” said Trzeciak. “And one of the things that we have been thinking through here at FDA, using CBD as an example, is what does the regulatory framework for those products look like?”
Continue reading